Amalgam Rx, Inc., has announced the expansion of its global agreement with Novo Nordisk for the commercialization of its digital insulin initiation and titration app, Dose Check.
Amalgam Rx is a leader in connecting healthcare providers and life sciences companies through a SaaS-enabled digital marketplace and product platform while Novo Nordisk is the world's leading diabetes care company. Dose Check is an app developed to help people with type 2 diabetes using basal insulin.
The new agreement bolsters the existing partnership and product suite between Novo Nordisk and Amalgam by incorporating and integrating with connected insulin delivery devices, continuous glucose monitors, and electronic health records (EHRs).
Thomas Thestrup-Terp, Corporate Vice President, Digital Strategy & Solutions, Novo Nordisk, said, “We’re expanding Dose Check’s geographic footprint and simplifying the way people living with diabetes and HCPs access digital health solutions. We are now investing further in our partnership with Amalgam with the ambition to use innovative digital health solutions to further improve personalized care for people living with diabetes.”
Novo Nordisk is also making an equity investment in Amalgam.
Join the HealthXL Webinar on ‘Retail Healthcare: Current and Future Opportunities for Digital Health’ on 26th January. Click here to Request to Join.
Click here to read the original news story.